Investment
Features
FeesSafety
Academy
More
Pluang+

Compare International Business Machines Corp (IBM) vs Viatris Inc (VTRS) Price & Performance

International Business Machines CorpTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

International Business Machines Corp vs Viatris Inc — how do they compare? International Business Machines Corp trades at $226.98 (market cap $213.50B), while Viatris Inc trades at $17.61 (market cap $20.03B). The key difference: International Business Machines Corp is far larger — about 10.7× Viatris Inc's market cap, and International Business Machines Corp pays the higher dividend (2.98%). Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 88 Days and Viatris Inc for 57 Days on average.

IBMVTRS
Market Cap
$213.50B$20.03B
Volume
8,908,68714,109,977
Sector
TechnologyHealth
52-Week High
$329.23$18.27
52-Week Low
$205.77$9.74
Typical Hold Time
88 Days57 Days
Enterprise Value
$270.64B$32.15B
Dividend Yield
2.98%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

International Business Machines Corp

IBM stock trades at $227.44, up 3.14% with recent momentum driven by positive sentiment in the consulting sector following Accenture's strong earnings. The company shows solid fundamentals with 2025 revenue of $67.54B and net income of $10.59B, though technical indicators suggest bearish momentum with the stock trading near resistance at $230. Recent developments include the self-hosted deployment option for IBM Bob AI platform, enhancing enterprise AI sovereignty capabilities.

IBM presents a mixed investment case with strong profitability metrics (15.52% net margin, 34.62% ROE) and analyst consensus price target of $255.50 offering 12% upside potential. However, bearish technical signals, recent earnings miss in Q2 2026, and increased investing cash outflows (-$10.3B in 2025) present near-term headwinds. The stock's valuation at 20.13 P/E appears reasonable given the company's hybrid cloud and AI consulting growth trajectory.

Viatris Inc

Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.

The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IBM
54% Buy46% Sell
Avg holding period · 88 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About International Business Machines Corp

International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.

Read more on IBM →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →